There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ObsEva SA (NASDAQ:OBSV), AstraZeneca (NYSE:AZN) and Bluebird Bio (NASDAQ:BLUE) with bullish sentiments.
ObsEva SA (OBSV)
Wedbush analyst Liana Moussatos initiated coverage with a Buy rating on ObsEva SA today and set a price target of $34. The company’s shares opened today at $14.32.
According to TipRanks.com, Moussatos is a 3-star analyst with an average return of 2.8% and a 43.2% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Catabasis Pharmaceuticals, and Global Blood Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ObsEva SA with a $30.25 average price target, representing an 111.2% upside. In a report issued on July 25, H.C. Wainwright also reiterated a Buy rating on the stock with a $30 price target.
.
See today’s analyst top recommended stocks >>
AstraZeneca (AZN)
In a report released today, Alex Arfaei from BMO Capital maintained a Buy rating on AstraZeneca, with a price target of $45. The company’s shares opened today at $38.28, close to its 52-week high of $39.25.
According to TipRanks.com, Arfaei is a 4-star analyst with an average return of 7.1% and a 70.8% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Merck & Company, Eli Lilly & Co, and Bristol Myers.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AstraZeneca with a $43.50 average price target.
Bluebird Bio (BLUE)
Cowen & Co. analyst Chris Shibutani reiterated a Buy rating on Bluebird Bio today. The company’s shares opened today at $155.15.
According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 10.6% and a 39.4% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.
Currently, the analyst consensus on Bluebird Bio is a Moderate Buy with an average price target of $217.30, a 40.1% upside from current levels. In a report issued on August 2, William Blair also maintained a Buy rating on the stock.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
